Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

Journal of Cellular Physiology

Volumn 226, Issue 1, 2011, Pages 52-57

  Vazquez Martin, Alejandro ^a,b   Oliveras Ferraros, Cristina ^a,b   Cufí, Silvia ^a,b   Del Barco, Sonia ^a,b   Martin Castillo, Begoña ^a,b   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; TRASTUZUMAB;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL DIVISION; CELL MEMBRANE; DRUG RESISTANCE; DRUG RESPONSE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 78049309932     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22333     Document Type: Article

References (23)

1. Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J. 2003. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283.
2. Berenbaum MC. 1989. What is synergy? Pharmacol Rev 41: 93-193.
3. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. 2008. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112: 533-543.
4. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massutí A, Cortes-Funes H, Lloveras B. 2000. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356-2362.
5. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. 1987. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Washington, DC) 237: 178-182.
6. DiGiovanna MP, Stern DF. 1995. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res 55: 1946-1955.
7. Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM. 2010. Shed HER2 extracellular domain in HER2-mediated tumor growth and in Trastuzumab susceptibility. J Cell Physiol 225: 256-265.
8. Hudelist G, Kostler WJ, Attems J, Czerwenka K, Muller R, Manavi M, Steger GG, Kubista E, Zielinski CC, Singer CF. 2003. Her-2/neu-triggered intracellular tyrosine kinase activation: In vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 89: 983-991.
9. Köninki K, Barok M, Tanner M, Staff S, Pitkänen J, Hemmilä P, Ilvesaro J, Isola J. 2010. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 294: 211-219.
10. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, Leyland-Jones B. 2009. Utility of serum HER2 extracellular domain assessment in clinical decision making: Pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 27: 1685-1693.
11. Menendez JA, Vazquez-Martin A, Colomer R, Brunet J, Carrasco-Pancorbo A, Garcia-Villalba R, Fernandez-Gutierrez A, Segura-Carretero A. 2007. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. BMC Cancer 7: 80.
12. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. 2001. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749.
13. Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM. 2005. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65: 473-482.
14. Nahta R, Shabaya S, Ozbay T, Rowe DL. 2009. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: What we have learned from clinical specimens. Curr Pharmacogenomics Person Med 7: 263-274.
15. Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Barco SD, Lopez-Bonet E, Brunet J, Menendez JA. 2010. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun 397: 27-33.
16. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, Di CS, Matias-Guiu X, Cajal S, Arribas J, Baselga J. 2007. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628-638.
17. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon Y, Cajal S, Arribas J, Baselga J. 2009. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28: 803-814.
18. Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, Sánchez G, Guzman M, Parra JL, Ellis C, Gagnon R, Koehler M, Gomez H, Geyer C, Cameron D, Arribas J, Rosen N, Baselga J. 2010. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 16: 2688-2695.
19. Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA. 1988. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 8: 5570-5574.
20. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J. 2004. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3: 1585-1592.
21. Vazquez-Martin A, Oliveras-Ferraros C, Colomer R, Brunet J, Menendez JA. 2008. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann Oncol 19: 1097-1109.
22. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. 2009. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One 4: e6251.
23. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes D. 1995. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 18-25.